The current pharmacotherapy of Alzheimer’s disease based on cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and memantine is well tolerated by patients and safely used in terms of hepatotoxicity risk. The gene discussed is BCHE; the disease is Alzheimer disease.